Boston Scientific Stock Falls After Q3 Earnings Miss, Guidance Cut

Boston Scientific (NYSE: BSX) shares fell sharply in pre-market trading after the company reported mixed third-quarter results and cut its financial outlook, pointing to disruptions from a recent cyberattack.

Investors reacted negatively to a combination of an earnings miss, a significant reduction in forward guidance, and contracting margins, sending the stock toward its 52-week low.

Earnings Miss and Lowered Outlook

The medical device manufacturer's report presented a challenging picture for investors. While net sales grew 1.5% year-over-year to $5.14 billion, narrowly beating analyst estimates, the bottom line fell short of expectations.

Key figures from the Q3 2026 report and updated guidance include:

• Adjusted EPS: $0.73, missing the consensus estimate of $0.75.
• Q4 2026 Guidance: The company projects adjusted EPS of $0.77–$0.79, well below the analyst consensus of $0.83.
• Full-Year 2026 Guidance: The forecast for adjusted EPS was trimmed to $3.16–$3.18, a notable decrease from the prior range of $3.28–$3.32.
• Sales Forecast: Management also projected that net sales would decline year-over-year in the fourth quarter.

Cyberattack and Margin Pressure

Ad

Boston Scientific's management attributed the weakened forecast to the ongoing effects of an August 25 cyberattack. The incident disrupted manufacturing, order processing, and global shipments, leading the company to withdraw its original 2026 forecasts in September.

The operational impact was also visible in the company's profitability. Adjusted operating margin contracted sharply to 16.1% in the third quarter, down from 20.7% in the same period a year earlier, reflecting the financial toll of the disruption.

Competitive and Market Context

Beyond the cyberattack, the company faces other headwinds. The report noted that competitive pressures have been a factor, with Medtronic’s Sphere-9 catheter gaining market share in the U.S. electrophysiology market against Boston Scientific’s FARAPULSE franchise. Demand for its WATCHMAN device has also remained soft, according to the source material.

The broader market offered little support for the stock, with the S&P 500 and Dow Jones Industrial Average trading nearly flat. The combination of the earnings miss, guidance cut, and unresolved operational issues fueled investor concerns over the company's near-term growth and profitability.